Menu Close

News

8.15.22 – Moderna CEO Touts Plan For Triple Combo Respiratory Shot In “Three to Five Years”: Report 

During the worst of the COVID-19 pandemic, Moderna worked its way into the public consciousness by speeding an effective vaccine through the FDA authorization process. But as demand slows for the first generation of coronavirus vaccines, Moderna is laying plans to build out its portfolio in the years to come.

Alongside its planned omicron-targeting shots for this fall, Moderna expects a combination COVID, flu and respiratory syncytial virus shot will be developed over “three to five years,” CEO Stéphane Bancel told CNN Business.

8.10.22 – Join GSK Professionals For a  Webinar Program To Provide Disease Education For Meningococcal Serogroup B 

The purpose of the program is to provide disease education on meningococcal serogroup B,  including meningococcal B vaccination and the Advisory Committee on Immunization. Practices (ACIP) recommendations. 

  • Thursday – August 11th, 2022 @ 1:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Joseph Domachowske
  • Wednesday – August 24th, 2022 @ 12:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Anita Chandra-Puri
  • Thursday – August 25th, 2022 @ 1:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Joseph Domachowske
  • Tuesday – August 30th, 2022 @ 3:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Joseph Domachowske
  • Tuesday – September 13th, 2022 @ 12:15 ET – Disease Education On Meningococcal Serogroup B with Dr. Jeffrey Cooper
  • Wednesday – September 21st, 2022 @ 6:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Jeffrey Cooper 
  • Tuesday – September 30th, 2022 @ 1:15 PM ET – Disease Education On Meningococcal Serogroup B with Dr. Joseph Domachowske

7.22.22 – Bavarian Nordic receives positive CHMP opinion on the extension of vaccine label to include Monkeypox

COPENHAGEN, Denmark, July 22, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the marketing authorization for the Company’s smallpox vaccine, IMVANEX®, is extended to include protecting people from monkeypox disease. 

Data supporting the positive opinion was submitted upon request from EMA’s Emergency Task Force (ETF) in light of the current multi-country monkeypox outbreak.

The recommendation from the CHMP will be referred to the European Commission (EC) for final approval shortly. Once granted by the EC, the extended marketing authorization will be valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway.